- STADA appoints former Scholl CEO Craig Shaw to lead UK business to new heights in Consumer Healthcare, Generics and Specialty.
- Shaw’s deep marketing and commercial experience to help power growth for brands including Nizoral, Cetraben, Covonia, Savlon, Hedrin and Zoflora.
- STADA CEO Peter Goldschmidt: “We are, under Craig’s experienced leadership, embarking on a new chapter of growth in the UK, including by actively seeking attractive acquisition opportunities to strengthen our portfolio and pipeline of Consumer Healthcare, Generics and Specialty products.”
STADA has appointed Craig Shaw as its General Manager in the UK. Bringing over 25 years of senior leadership experience in the health and personal care industry, Shaw held executive roles at organisations including Scholl’s Wellness Company, Reckitt Benckiser, and Novartis Consumer Healthcare. Most recently, he served as CEO of Scholl, where he successfully led its transformation into a fully operational stand-alone enterprise.
Peter Goldschmidt, Chief Executive Officer of STADA, commented: “With the UK ranking among STADA’s five largest countries by revenues, accelerating UK growth organically and inorganically is a key strategic priority. We are, under Craig’s experienced leadership, embarking on a new chapter of growth in the UK, including by actively seeking attractive acquisition opportunities to strengthen our portfolio and pipeline of Consumer Healthcare, Generics and Specialty products.”
Craig’s proven track record in scaling businesses, enhancing brand equity, and expanding healthcare portfolios will be instrumental in driving commercial performance across the three pillars of the STADA strategy: Consumer Healthcare, Generics and Specialty.
Craig stated: “STADA’s agility and consistent outperformance within the industry have long impressed me. I’m excited to join the team and unlock the full potential of our established brands including Nizoral, Zoflora, Cetraben, Covonia, Hedrin, and Savlon. At the same time, we will continue to build momentum in our Specialty portfolio.”
“There’s a talented and entrepreneurial team here, and we’re going to reenergise to really leverage our diverse brand portfolio. I’m looking forward to driving STADA UK to reach its next phase of growth, and we’ll do that by supporting customers, healthcare professionals, suppliers and communities across the UK with great products and treatments they need.”
The UK ranks among STADA’s top-five countries, accounting for approximately 7% of 2024 group revenues totalling €4.1 billion. Building on a heritage of more than 100 years in consumer healthcare and home hygiene, STADA UK supplies a broad range of prescription generic and specialty medicines across therapeutic categories including dermatology, respiratory, oncology and kidney disease.
Furthermore, the UK also forms an essential part of STADA’s global manufacturing and supply-chain network. The Thornton & Ross factory near Huddersfield serves as a centre of excellence for liquids and semi-solids such as creams and ointments, producing a diverse range of OTC and prescription products. Through the Natures Aid facility in Preston, STADA UK also produces and packages a range of herbal medicines and food supplements in the form of tablets, capsules, powders and liquids.
